tiprankstipranks
Trending News
More News >
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
Advertisement

NRX Pharmaceuticals (NRXP) Stock Statistics & Valuation Metrics

Compare
497 Followers

Total Valuation

NRX Pharmaceuticals has a market cap or net worth of $62.51M. The enterprise value is $65.79M.
Market Cap$62.51M
Enterprise Value$65.79M

Share Statistics

NRX Pharmaceuticals has 23,769,901 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding23,769,901
Owned by Insiders7.78%
Owned by Institutions9.66%

Financial Efficiency

NRX Pharmaceuticals’s return on equity (ROE) is 1.08 and return on invested capital (ROIC) is 111.15%.
Return on Equity (ROE)1.08
Return on Assets (ROA)-6.88
Return on Invested Capital (ROIC)111.15%
Return on Capital Employed (ROCE)1.02
Revenue Per Employee0.00
Profits Per Employee-12.56M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of NRX Pharmaceuticals is ―. NRX Pharmaceuticals’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-1.00
Price to FCF
Price to Operating Cash Flow-3.61
PEG Ratio

Income Statement

In the last 12 months, NRX Pharmaceuticals had revenue of 0.00 and earned -25.13M in profits. Earnings per share was -2.39.
Revenue0.00
Gross Profit-5.00K
Operating Income-18.50M
Pretax Income-25.13M
Net Income-25.13M
EBITDA-24.04M
Earnings Per Share (EPS)-2.39

Cash Flow

In the last 12 months, operating cash flow was -11.91M and capital expenditures 0.00, giving a free cash flow of -11.91M billion.
Operating Cash Flow-11.91M
Free Cash Flow-11.91M
Free Cash Flow per Share-0.50

Dividends & Yields

NRX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.01
52-Week Price Change34.76%
50-Day Moving Average2.92
200-Day Moving Average2.46
Relative Strength Index (RSI)43.31
Average Volume (3m)336.00K

Important Dates

NRX Pharmaceuticals upcoming earnings date is Nov 17, 2025, Before Open (Confirmed).
Last Earnings DateAug 19, 2025
Next Earnings DateNov 17, 2025
Ex-Dividend Date

Financial Position

NRX Pharmaceuticals as a current ratio of 0.15, with Debt / Equity ratio of -33.37%
Current Ratio0.15
Quick Ratio0.15
Debt to Market Cap0.28
Net Debt to EBITDA-0.28
Interest Coverage Ratio-17.15

Taxes

In the past 12 months, NRX Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

NRX Pharmaceuticals EV to EBITDA ratio is -1.53, with an EV/FCF ratio of -2.66.
EV to Sales0.00
EV to EBITDA-1.53
EV to Free Cash Flow-2.66
EV to Operating Cash Flow-2.66

Balance Sheet

NRX Pharmaceuticals has $2.91M in cash and marketable securities with $10.23M in debt, giving a net cash position of $7.32M billion.
Cash & Marketable Securities$2.91M
Total Debt$10.23M
Net Cash$7.32M
Net Cash Per Share$0.31
Tangible Book Value Per Share-$2.21

Margins

Gross margin is 25.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin25.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%

Analyst Forecast

The average price target for NRX Pharmaceuticals is $29.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$29.50
Price Target Upside1070.63% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast18.51%

Scores

Smart Score7
AI Score45
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis